AG
TBPH icon

Aperio Group’s Theravance Biopharma TBPH Stock Holding History

Aperio Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$218K Sell
12,235
-1,496
-11% -$26.9K ﹤0.01% 2287
2020
Q3 		$203K Sell
13,731
-2,837
-17% -$53.1K ﹤0.01% 2229
2020
Q2 		$348K Sell
16,568
-1,933
-10% -$49.7K ﹤0.01% 1958
2020
Q1 		$428K Buy
18,501
+2,738
+17% +$68.5K ﹤0.01% 1732
2019
Q4 		$408K Sell
15,763
-1,874
-11% -$36.4K ﹤0.01% 1918
2019
Q3 		$343K Buy
17,637
+6,705
+61% +$135K ﹤0.01% 1959
2019
Q2 		$178K Sell
10,932
-1,132
-9% -$22.9K ﹤0.01% 2216
2019
Q1 		$274K Buy
12,064
+3,652
+43% +$92.6K ﹤0.01% 2048
2018
Q4 		$215K Buy
8,412
+2,255
+37% +$60.9K ﹤0.01% 2094
2018
Q3 		$201K Buy
+6,157
New +$168K ﹤0.01% 2191
2017
Q3 		– Sell
-5,144
Closed -$205K – 2237
2017
Q2 		$205K Buy
+5,144
New +$198K ﹤0.01% 2089

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aperio Group's TBPH Position: Q4 2020 in Review

Aperio Group reduced its Theravance Biopharma (TBPH) stake by 11% in Q4 2020, selling an estimated $26.9K and leaving 12,235 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #2287.

Aperio Group first reported a position in TBPH in Q2 2017 and has held it in 11 quarters since. The position peaked at $428K in Q1 2020. 107 funds tracked by Wall St. Rank hold TBPH as of Q4 2020.

  • Aperio Group held 12,235 shares of Theravance Biopharma worth $218K as of Q4 2020.
  • Aperio Group sold 1,496 Theravance Biopharma shares in Q4 2020, an estimated $26.9K.
  • Theravance Biopharma made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2287 holding.
  • Aperio Group first reported a position in Theravance Biopharma in Q2 2017 and has held it in 11 quarters since.
  • Aperio Group's Theravance Biopharma position peaked at $428K in Q1 2020.
  • 107 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.